Why Kodak is perfectly positioned to pivot to pharmaceuticals

Last week, the US federal government announced a first-of-its-kind loan to Eastman Kodak, a US-based company once known for its leadership in the film photography industry. Kodak will be using the $765 million to begin producing components for generic drugs—specifically, active pharmaceutical ingredients (APIs), the chemicals that make a drug work. “In the world of chemicals, we have a lot of chemicals that are building blocks—like LEGOs,” says Frankie Wood-Black, a physical chemist currently teaching at Northern Oklahoma College who has 25 years of experience in industrial chemical manufacturing.